Home LiteratureArticle Details
PMID: 8969245 Published · ppublish English Journal Article Review

New vaccines for the prevention of pneumococcal infections.

Emerging infectious diseases ·Vol. 2 ·No. 4 ·1996-00-00 ·Pages 289-98

Käyhty H, Eskola J

Abstract

Streptococcus pneumoniae is a major cause of acute otitis media, pneumonia, bacteremia, and meningitis. Because in recent years antibiotic-resistant pneumococcal strains have been emerging throughout the world, vaccination against pneumococcal infections has become more urgent. The capsular polysaccharide vaccine that has been available is neither immunogenic nor protective in young children and other immunocompromised patients. Several pneumococcal proteins have been proposed as candidate vaccines, but no human studies associated with them have been reported. Clinical trials of first-generation pneumococcal conjugate vaccines have shown that covalent coupling of pneumococcal capsular polysaccharides to protein carriers improves the immunogenicity of the polysaccharides. The protective efficacy of the conjugate vaccines against carriage, acute otitis media, and invasive infections is being studied.

MeSH Terms
Adult Bacteremia/immunology,prevention & control Bacterial Proteins/immunology Carrier State/immunology Child Child, Preschool Clinical Trials as Topic/methods Humans Immunocompromised Host Infant Meningitis, Pneumococcal/immunology,prevention & control Otitis Media/immunology,prevention & control Pneumococcal Infections/immunology,prevention & control Pneumonia, Pneumococcal/immunology,prevention & control Polysaccharides, Bacterial/immunology Streptococcus pneumoniae/immunology Vaccination Vaccines/immunology Vaccines, Conjugate/immunology
Chemicals
Bacterial Proteins Polysaccharides, Bacterial Vaccines Vaccines, Conjugate
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Käyhty H
Department of Vaccines, National Public Health Institute, Helsinki, Finland. helena.kayhty@ktl.fi
Eskola J
References (47)
47 references, click to expand
  1. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.
    Lancet. 1986 Oct 18;2(8512):877-81 PMID: 2876325
  2. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.
    Infect Immun. 1991 Aug;59(8):2750-7 PMID: 1855991
  3. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants.
    Pediatr Infect Dis J. 1996 Apr;15(4):333-9 PMID: 8866803
  4. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.
    Infect Immun. 1986 May;52(2):519-28 PMID: 3516876
  5. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats.
    J Infect Dis. 1993 Feb;167(2):365-71 PMID: 8421170
  6. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.
    J Infect Dis. 1996 Jan;173(1):119-27 PMID: 8537648
  7. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children.
    J Pediatr. 1993 Nov;123(5):801-10 PMID: 8229496
  8. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants.
    J Pediatr. 1996 May;128(5 Pt 1):649-53 PMID: 8627437
  9. Pneumococcal vaccine and otitis media.
    Lancet. 1980 Sep 13;2(8194):547-51 PMID: 6106735
  10. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.
    Infect Immun. 1994 Dec;62(12):5683-8 PMID: 7960154
  11. Pneumococcal bacteremia in Monroe County, New York.
    Am J Public Health. 1992 Nov;82(11):1513-6 PMID: 1443302
  12. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.
    J Infect Dis. 1996 Feb;173(2):380-6 PMID: 8568299
  13. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.
    N Engl J Med. 1990 Nov 15;323(20):1381-7 PMID: 2233904
  14. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
    N Engl J Med. 1991 Nov 21;325(21):1453-60 PMID: 1944423
  15. Acute respiratory infections in the developing world: strategies for prevention, treatment and control.
    Pediatr Infect Dis J. 1987 Jul;6(7):622-9 PMID: 3302915
  16. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid).
    J Immunol. 1987 Sep 15;139(6):1999-2004 PMID: 3497985
  17. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults.
    J Infect Dis. 1996 Apr;173(4):1014-8 PMID: 8603942
  18. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.
    Infect Immun. 1988 Sep;56(9):2292-8 PMID: 3410538
  19. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.
    Infect Immun. 1992 Dec;60(12):4977-83 PMID: 1452327
  20. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine.
    Lancet. 1995 Nov 11;346(8985):1252-7 PMID: 7475716
  21. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods.
    Scand J Infect Dis. 1981;13(3):177-83 PMID: 7313573
  22. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines.
    J Infect Dis. 1995 Jan;171(1):99-105 PMID: 7798688
  23. Pneumococcal resistance to antibiotics.
    Clin Microbiol Rev. 1990 Apr;3(2):171-96 PMID: 2187594
  24. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.
    Infect Immun. 1995 Mar;63(3):961-8 PMID: 7532630
  25. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine.
    Pediatr Infect Dis J. 1993 Jun;12(6):478-84 PMID: 8345980
  26. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.
    Clin Diagn Lab Immunol. 1995 Sep;2(5):590-7 PMID: 8548539
  27. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics.
    Pediatr Infect Dis J. 1994 May;13(5):368-72 PMID: 8072818
  28. Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins.
    Infect Immun. 1994 Jan;62(1):319-24 PMID: 7505262
  29. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.
    Vaccine. 1994 Aug;12(10):875-8 PMID: 7975828
  30. Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group.
    JAMA. 1992 Dec 16;268(23):3328-32 PMID: 1364814
  31. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia.
    JAMA. 1996 Apr 17;275(15):1182-8 PMID: 8609686
  32. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.
    JAMA. 1993 Oct 20;270(15):1826-31 PMID: 8411526
  33. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly.
    J Infect Dis. 1996 Feb;173(2):387-93 PMID: 8568300
  34. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.
    Infect Immun. 1991 Jan;59(1):222-8 PMID: 1987036
  35. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : I. THE SYNTHESIS OFp-AMINOPHENOL beta-GLUCOSIDE, p-AMINOPHENOL beta-GALACTOSIDE, AND THEIR COUPLING WITH SERUM GLOBULIN.
    J Exp Med. 1929 Sep 30;50(4):521-31 PMID: 19869644
  36. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines.
    Pediatr Infect Dis J. 1995 Apr;14(4):286-94 PMID: 7603810
  37. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.
    Infect Immun. 1992 Sep;60(9):3528-32 PMID: 1500160
  38. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae.
    Microb Pathog. 1988 Dec;5(6):461-7 PMID: 3149709
  39. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media.
    J Infect Dis. 1993 Feb;167(2):347-55 PMID: 8421168
  40. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.
    Pediatr Infect Dis J. 1996 Feb;15(2):134-9 PMID: 8822286
  41. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.
    J Infect Dis. 1995 Nov;172(5):1273-8 PMID: 7594664
  42. Epidemiology of invasive pneumococcal infections in children in Finland.
    JAMA. 1992 Dec 16;268(23):3323-7 PMID: 1453524
  43. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae.
    Infect Immun. 1983 May;40(2):548-52 PMID: 6840851
  44. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid.
    J Infect Dis. 1987 Jan;155(1):100-6 PMID: 3491858
  45. IgG subclasses of pneumococcal antibodies--effect of allotype G2m(n).
    Scand J Immunol. 1989 Feb;29(2):229-37 PMID: 2922573
  46. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies.
    Pediatr Infect Dis J. 1995 Jun;14(6):503-10 PMID: 7667055
  47. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T.
    Lancet. 1994 Aug 6;344(8919):362-6 PMID: 7914306
Article Info
Journal
Emerging infectious diseases
Abbr.
Emerg Infect Dis
ISSN
1080-6040
DOI
10.3201/eid0204.960404
Email
helena.kayhty@ktl.fi
Published
1996-00-00
Pages
289-98
Language
English
Region
United States
NLM ID
9508155
PMCID
PMC2639933
Subset
IM
External Links
PubMed source DOI: 10.3201/eid0204.960404 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2